MarginScan seeks to support Mohs surgery procedures for skin cancer treatment with real-time margin detection for NMSC.

PHC Corporation and NovaScan, Inc. are joining forces  to explore the feasibility of MarginScan, an investigational ex vivo device that aims to support physicians in detecting non-melanoma skin cancers (NMSC).

One of the proposed uses of MarginScan is to seek to support Mohs surgery procedures for skin cancer treatment with real-time margin detection for NMSC. MarginScan may help reduce patient morbidity and improve outcomes for both patients and clinicians. 

 “We look forward to collaborating with NovaScan to provide high-value-added solutions in the pathology diagnostics field, leveraging our expertise in highly reliable medical device development,” sats Hiroyuki Tokunaga, Member of the Board of PHC and Director of its In Vitro Diagnostics Division in a news release. “PHC is also committed to accelerating the development of point-of-care technology that enables highly convenient testing, to contribute to our mission of improving the quality of healthcare around the world.”

NovaScan CEO Craig Davis adds, “We are positively thrilled to be collaborating with PHC Group, a world class provider of oncology diagnostics solutions and medical devices. Our platform technology enables in vivo and ex vivo cancer detection, in real time and without expensive capital equipment or the need for steep clinician learning curves. We believe that MarginScan has the potential to be employed in standard of care procedures for the most common cancers in the world. PHC is a collaboration partner that can make this a reality, in skin cancer and beyond.”